+ News | etiraRx News | etiraRx News

News

June 1, 2023

One year later, highest almetric score for any paper published in Nature Cancer!

Dallas, Texas. June 1, 2023: One year after its online publication, we are pleased to note that our manuscript titled “Targeting LIPA independent of its lipase activity is a therapeutic...

April 18, 2023

Positive preclinical data presented at AACR 2023

Dallas, Texas. April 18, 2023: Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The...

April 17, 2023

Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award

Dallas, Texas. April 17, 2023: We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics...

December 9, 2022

Preclinical data on TNBC presented at SABCS 2022

Dallas, Texas. December 9, 2022: Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast...

October 31, 2022

Etira founder Dr. Jung-Mo Ahn highlighted in local press

Dallas, Texas. October 31, 2022. We are pleased to share two news articles from Dallas that describe how our brilliant chemist and founder, Dr. Jung-Mo Ahn discovered ERX-41. In his...

October 10, 2022

Oncology Times Highlights ERX-41

Dallas, Texas. October 10, 2022: etiraRx's lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled "Molecule Targets Vulnerability in Triple-Negative...

September 23, 2022

Etira selected as a 2022 BioNTX rising star

Dallas Texas, September 23, 2022. We are pleased to announce that Etira has been selected as a 2022 BioNTX rising star. The BioNTX iC³ Life Science Summit is a two-day...

July 10, 2022

ERX-41 Paper image selected for Nature Cancer cover

Dallas, Texas. July 7, 2022: On the cover of the July 2022 issue of Nature cancer is an image of the endoplasmic reticulum within a cell. Image courtesy of Dr....

July 1, 2022

Scientific News Media Features the Discovery of ERX-41, the Novel Mechanism of Action and Novel Molecular Target

Dallas, Texas.  July 1, 2022: Following the publication of the article “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum...

June 3, 2022

EtiraRx’s Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers, Company Prepares for Clinical Trials

Dallas, Texas. June 2, 2022:  /PRNewswire/ -- A scientific team, led by the scientific founders of EtiraRx, has identified a small molecule, ERX-41, as a novel oral therapeutic agent that...